Exact Mass: 824.3512912
Exact Mass Matches: 824.3512912
Found 68 metabolites which its exact mass value is equals to given mass value 824.3512912,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Vincristine
Vincristine appears as a white crystalline solid. Melting point 218 °C. Used as an antineoplastic. Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine. Vincristine is a natural product found in Ophioparma ventosa, Cunila, and other organisms with data available. Vincristine is a natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04) Vincristine is only found in individuals that have used or taken this drug. It is an antitumor alkaloid isolated from Vinca Rosea. (Merck, 11th ed.) The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkins disease, acute erythraemia, and acute panmyelosis. Vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy). An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.) See also: Vincristine Sulfate (active moiety of). Vincristine is only found in individuals that have used or taken this drug. It is an antitumor alkaloid isolated from Vinca Rosea. (Merck, 11th ed.)The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis. A vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01C - Plant alkaloids and other natural products > L01CA - Vinca alkaloids and analogues C274 - Antineoplastic Agent > C1931 - Antineoplastic Plant Product > C932 - Vinca Alkaloid Compound C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent D050258 - Mitosis Modulators > D050256 - Antimitotic Agents > D050257 - Tubulin Modulators D000970 - Antineoplastic Agents > D050256 - Antimitotic Agents D000970 - Antineoplastic Agents > D014748 - Vinca Alkaloids C1907 - Drug, Natural Product
(2b,3b)-Dihydroxy-30-nor-12,20(29)-oleanadiene-28-glucopyranosyloxy-23-oic acid 3-glucuronide
(2b,3b)-Dihydroxy-30-nor-12,20(29)-oleanadiene-28-glucopyranosyloxy-23-oic acid 3-glucuronide is found in cereals and cereal products. (2b,3b)-Dihydroxy-30-nor-12,20(29)-oleanadiene-28-glucopyranosyloxy-23-oic acid 3-glucuronide is a constituent of Amaranthus cruentus (purple amaranth) Constituent of Amaranthus cruentus (purple amaranth). (2b,3b)-Dihydroxy-30-nor-12,20(29)-oleanadiene-28-glucopyranosyloxy-23-oic acid 3-glucuronide is found in cereals and cereal products and green vegetables.
6,7-Didehydrofevicordin F 3-[glucosyl-(1->6)-glucoside]
6,7-Didehydrofevicordin F 3-[glucosyl-(1->6)-glucoside] is found in fruits. 6,7-Didehydrofevicordin F 3-[glucosyl-(1->6)-glucoside] is a constituent of Cyclanthera pedata (achoccha) Constituent of Cyclanthera pedata (achoccha). 6,7-Didehydrofevicordin F 3-[glucosyl-(1->6)-glucoside] is found in fruits.
Aclacinomycin X
C42H52N2O15 (824.3367522000001)
D000970 - Antineoplastic Agents D007155 - Immunologic Factors
Leurocristine
PGP(i-12:0/PGJ2)
C38H66O15P2 (824.3876746000001)
PGP(i-12:0/PGJ2) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-12:0/PGJ2), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of Prostaglandin J2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).
PGP(PGJ2/i-12:0)
C38H66O15P2 (824.3876746000001)
PGP(PGJ2/i-12:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(PGJ2/i-12:0), in particular, consists of one chain of one Prostaglandin J2 at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).
B, H2SO4-Vincristine, BAN, INN|Vincristine, BAN, INN
methyl 4-(acetyloxy)-15-[3-formyl-7-(methoxycarbonyl)-5-(2-oxobutyl)-1,2,3,4,5,6,7,8-octahydroazonino[5,4-b]indol-7-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
Aclacinomycin X
C42H52N2O15 (824.3367522000001)
D000970 - Antineoplastic Agents D007155 - Immunologic Factors
(3E,8E)-2alpha,7beta,9,10beta,13alpha,20-hexaacetoxy-5(2-acetoxy-cinnamoyloxy)-3,8-secotaxa-3,8,11-triene
4A-alpha-L-rhodinosyl-3-alpha-L-rhodinosyl-4C->1D-alpha-L-aculosylaquayamycin|saquayamycin K
4A-alpha-L-cinerulosyl-3-alpha-L-rhodinosyl-4C->1D-alpha-L-rhodinosylaquayamycin|saquayamycin J
3beta,11beta-Dihydroxy-12-oxo-18-nor-5alpha-card-13-enolid-3beta-O-(3-O-acetyl-beta-D-digitoxosido-beta-D-xylosido-alpha-L-rhamnosid)|3beta,11beta-Dihydroxy-12-oxo-18-nor-5alpha-card-13-enolid-3beta-O-<3-O-acetyl-beta-D-digitoxosido-beta-D-xylosido-alpha-L-rhamnosid>
(2b,3b)-Dihydroxy-30-nor-12,20(29)-oleanadiene-28-glucopyranosyloxy-23-oic acid 3-glucuronide
6,7-Didehydrofevicordin F 3-[glucosyl-(1->6)-glucoside]
DMT-dG(dmf)-CE-Phosphoramidite
DMT-dG(dmf) Phosphoramidite is a phosphinamide monomer that can be used in the preparation of oligonucleotides
[4R-(4alpha,5alpha,6alpha,7alpha)]-3,3-{{Tetrahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepine-1,3(2H)-diyl]bis(methylene)]bis[N-1H-benzimidazol-2-ylbenzamide]
C49H44N8O5 (824.3434493999999)
Methyl (1R,9R,10S,11R,12S,19R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
Dimethyl 12-ethyl-4-(17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl)-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10,11-dicarboxylate
methyl (9R,10S,11S,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01C - Plant alkaloids and other natural products > L01CA - Vinca alkaloids and analogues
methyl (1S,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
methyl (1S,10S,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
3,4,6,12,13-pentakis(acetyloxy)-8-hydroxy-4,8,11,11-tetramethyl-14-[(2-methylpropanoyl)oxy]-7,18-dioxo-19-oxatricyclo[13.4.0.0²,⁶]nonadec-9-en-15-yl 2-methylpropanoate
methyl (1r,9r,10r,11r,12r,19s)-11-(acetyloxy)-12-ethyl-4-[(13r,15s,17r)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0⁴,¹².0⁵,¹⁰]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2(7),3,5,13-tetraene-10-carboxylate
methyl (1r,2r,4s)-4-{[(2r,4s,5s,6s)-5-{[(2s,4s,5s,6s)-5-{[(2r,6s)-3-amino-6-methyl-5-oxo-2,6-dihydropyran-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-(dimethylamino)-6-methyloxan-2-yl]oxy}-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylate
C42H52N2O15 (824.3367522000001)
4-(6-{5,14-dimethyl-6-oxo-2,4,9,13-tetraoxatricyclo[8.4.0.0³,⁸]tetradecan-12-yl}-1,5-dihydroxy-9,10-dioxoanthracen-2-yl)-3-({5-[(5-hydroxy-6-methyloxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-3-methylbutanoic acid
4a,8,12b-trihydroxy-9-{4-hydroxy-6-methyl-5-[(6-methyl-5-oxooxan-2-yl)oxy]oxan-2-yl}-3-methyl-3-({6-methyl-5-[(6-methyl-5-oxooxan-2-yl)oxy]oxan-2-yl}oxy)-2,4-dihydrotetraphene-1,7,12-trione
(3s)-4-{6-[(1r,3r,5s,8s,10r,12r,14r)-5,14-dimethyl-6-oxo-2,4,9,13-tetraoxatricyclo[8.4.0.0³,⁸]tetradecan-12-yl]-1,5-dihydroxy-9,10-dioxoanthracen-2-yl}-3-{[(2s,5r,6s)-5-{[(2s,5r,6s)-5-hydroxy-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-3-methylbutanoic acid
methyl 2-[(1s,3s,5z,7r,8e,11s,12s,13e,15s,17r,21r,23r,25s)-12,25-bis(acetyloxy)-1,11,21-trihydroxy-17-[(1r)-1-hydroxyethyl]-13-(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1³,⁷.1¹¹,¹⁵]nonacos-8-en-5-ylidene]acetate
methyl (1r,9r,10s,11r,12r,19r)-11-(acetyloxy)-12-ethyl-4-[(13s,15r,17s)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0⁴,¹².0⁵,¹⁰]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2(7),3,5,13-tetraene-10-carboxylate
(11r,16s)-13-{2-[2,4-dihydroxy-5-(3-methylbut-2-en-1-yl)phenyl]-5-hydroxy-7,7-dimethylfuro[2,3-f]chromene-3-carbonyl}-5,14-dihydroxy-4,15-bis(3-methylbut-2-en-1-yl)-8,17-dioxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-1(10),2,4,6,12,14-hexaen-9-one
4a,8,12b-trihydroxy-9-{4-hydroxy-5-[(5-hydroxy-6-methyloxan-2-yl)oxy]-6-methyloxan-2-yl}-3-methyl-3-({6-methyl-5-[(6-methyl-5-oxo-2,6-dihydropyran-2-yl)oxy]oxan-2-yl}oxy)-2,4-dihydrotetraphene-1,7,12-trione
(3r,4ar,12bs)-9-[(1r,3r,5s,8s,10r,12r,14r)-5,14-dimethyl-6-oxo-2,4,9,13-tetraoxatricyclo[8.4.0.0³,⁸]tetradecan-12-yl]-4a,8,12b-trihydroxy-3-{[(2s,5s,6s)-5-{[(2s,5s,6s)-5-hydroxy-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-3-methyl-2,4-dihydrotetraphene-1,7,12-trione
(2r,3r,4s,6r)-6-{[(1r,3br,5as,7s,9as,9bs,10r)-10-hydroxy-9a-methyl-11-oxo-1-[(3s)-5-oxooxolan-3-yl]-1h,2h,3h,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h-cyclopenta[a]phenanthren-7-yl]oxy}-3-{[(2s,3r,4r,5r)-3,4-dihydroxy-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-2-methyloxan-4-yl acetate
3-({3,4-dihydroxy-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl}oxy)-6-{[10-hydroxy-9a-methyl-11-oxo-1-(5-oxooxolan-3-yl)-1h,2h,3h,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h-cyclopenta[a]phenanthren-7-yl]oxy}-2-methyloxan-4-yl acetate
(1r,2r)-8-{[(2s,3r,4s,5s)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-2,7-dihydroxy-3a,6,9b,11a-tetramethyl-1-[(4e)-2,3,6-trihydroxy-6-methylhept-4-en-2-yl]-1h,2h,3h,3bh,11h-cyclopenta[a]phenanthren-10-one
(1r,2s,3e,5s,7r,8e,10r,13s)-2,7,9,10,13-pentakis(acetyloxy)-4-[(acetyloxy)methyl]-8,12,15,15-tetramethylbicyclo[9.3.1]pentadeca-3,8,11-trien-5-yl (2z)-2-(acetyloxy)-3-phenylprop-2-enoate
(3r,4ar,12bs)-4a,8,12b-trihydroxy-9-[(2r,4r,5s,6r)-4-hydroxy-5-{[(2s,5s,6s)-5-hydroxy-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]-3-methyl-3-{[(2s,5s,6s)-6-methyl-5-{[(2r,6s)-6-methyl-5-oxo-2,6-dihydropyran-2-yl]oxy}oxan-2-yl]oxy}-2,4-dihydrotetraphene-1,7,12-trione
2,7,9,10,13-pentakis(acetyloxy)-4-[(acetyloxy)methyl]-8,12,15,15-tetramethylbicyclo[9.3.1]pentadeca-3,8,11-trien-5-yl 2-(acetyloxy)-3-phenylprop-2-enoate
9-{5,14-dimethyl-6-oxo-2,4,9,13-tetraoxatricyclo[8.4.0.0³,⁸]tetradecan-12-yl}-4a,8,12b-trihydroxy-3-({5-[(5-hydroxy-6-methyloxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-3-methyl-2,4-dihydrotetraphene-1,7,12-trione
(4s,7s,13r,22r)-2,5,8,11,14,20-hexahydroxy-4-(1h-indol-3-ylmethyl)-7-[(4-methoxy-1h-indol-3-yl)methyl]-13,18,22-trimethyl-16-methylidene-24-thia-3,6,9,12,15,18,21,26-octaazabicyclo[21.2.1]hexacosa-1(25),2,5,8,11,14,20,23(26)-octaen-17-one
C40H44N10O8S (824.3064144000001)
(11r,16s)-13-[5,6-dihydroxy-2-(7-hydroxy-2,2-dimethylchromen-6-yl)-7-(3-methylbut-2-en-1-yl)-1-benzofuran-3-carbonyl]-5,14-dihydroxy-4,15-bis(3-methylbut-2-en-1-yl)-8,17-dioxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-1(10),2,4,6,12,14-hexaen-9-one
methyl 2-[12,25-bis(acetyloxy)-1,11,21-trihydroxy-17-(1-hydroxyethyl)-13-(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1³,⁷.1¹¹,¹⁵]nonacos-8-en-5-ylidene]acetate
2,5,8,11,14,20-hexahydroxy-4-(1h-indol-3-ylmethyl)-7-[(5-methoxy-1h-indol-3-yl)methyl]-13,18,22-trimethyl-16-methylidene-24-thia-3,6,9,12,15,18,21,26-octaazabicyclo[21.2.1]hexacosa-1(25),2,5,8,11,14,20,23(26)-octaen-17-one
C40H44N10O8S (824.3064144000001)
methyl (1r,2r,4s)-4-{[5-({5-[(3-amino-6-methyl-5-oxo-2,6-dihydropyran-2-yl)oxy]-4-hydroxy-6-methyloxan-2-yl}oxy)-4-(dimethylamino)-6-methyloxan-2-yl]oxy}-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylate
C42H52N2O15 (824.3367522000001)